BURNABY, British Columbia, January 18, 2016 /PRNewswire/ --
Growing technological advancements and anticipated launch of various pipeline drugs to drive non-small cell lung cancer treatments market in Europe
According to recently published Pharmaion report, "Europe Non-Small Cell Lung Cancer Treatments Market Opportunities, 2010 - 2020", the non-small cell lung cancer (NSCLC) treatments market in Europe is anticipated to cross US$ 3 billion by 2019. Growth in the market is anticipated on account of increasing NSCLC prevalence rate, continuous exposure to radiation and carcinogens and growing patient awareness. Moreover, late appearance of disease symptoms leads to delay in diagnosis and advancement in the cancer stage, which results in increasing the cost of the treatment, and thereby generate higher revenues for Europe NSCLC treatments market.
In Europe, majority of the lung cancer patients were found to be suffering from NSCLC in 2014, and the trend is anticipated to continue through 2020. With increasing prevalence of NSCLC among European citizens, the demand for the treatments and therapies is forecast to grow at a robust pace in the next five years. Moreover, anticipated launch of multiple drugs across different classes of therapies is further anticipated to aid the non-small cell lung cancer treatments market in Europe during 2015 - 2020. However, patent expiration of drug and increasing availability of generic medicine are posing a challenge to the NSCLC treatments market in Europe.
On the basis of therapy offered, the market has been segmented into four broad categories, namely, chemotherapy, radiotherapy, surgery and target therapy. Among these categories, chemotherapy segment dominated the Europe non-small cell lung cancer treatments market in 2014. With various number of new drug entrants, coupled with numerous clinical trials in pipeline, the segment is anticipated to continue its dominance in the Europe NSCLC treatments market through 2020. Country-wise, the largest share in Europe's NSCLC treatments market was captured by Germany, followed by France, Italy, Spain and the UK.
"Europe non-small cell lung cancer treatments market will continue to exhibit promising growth over the next five years. Innovation and new product launches by the existing as well as the new market players is the major factor anticipated to drive non-small cell lung cancer treatments market during the forecast period. Moreover, growing adoption of Video Assisted Thoracic Surgery, Photodynamic Therapy and Laser Therapy, coupled with increasing applications of monoclonal antibodies and immunotherapy are among the major factors driving Europe non-small cell lung cancer treatments market." said Mr. Karan Chechi, Research Director with Pharmaion, a research based global pharmaceutical and healthcare consulting firm.
"Europe Non-Small Cell Lung Cancer Treatments Market Opportunities, 2010 - 2020" has analyzed the potential of non-small cell lung cancer treatments market in Europe and provides statistics and information on market sizes, shares and trends. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment evaluation. Besides, the report also identifies and analyzes the emerging trends along with essential drivers and key challenges faced by the non-small cell lung cancer treatments market in Europe.
Pharmaion is a research based management consulting firm focused exclusively on Healthcare & Pharmaceutical industry. Led by a team of dynamic industry experts, Pharmaion provides its customers with high value market research and advisory services that helps them identify new market opportunities, growth engines and innovative ways to capture the market share. As a result, Pharmaion's clients lead rather than follow market trends. Pharmaion has developed a proprietary database which focuses on identifying the unexplored opportunities in Healthcare and Pharmaceutical industry.
Contact Phone: +1-646-862-0089